-
Mashup Score: 0Remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy - 1 year(s) ago
Han Zhu, MD, Stanford University, Standford, CA, discusses remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy. Fatality…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0
CTX130 yields sustained complete response in one patient with relapsed/refractory disease
Source: www.medpagetoday.comCategories: General Medicine News, Latest HeadlinesTweet
-
Mashup Score: 0
Judith Varner, PhD, University of California, San Diego, CA, discusses the latest developments in targeting myeloid cells for cancer immunotherapy…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 4Radiomic texture patterns on CT scans as biomarker of early response to CDK4/6 inhibitors in HR+ mBC - 1 year(s) ago
Anant Madabhushi, PhD, Emory University School of Medicine, Atlanta, GA, discusses changes in radiomic texture patterns on CT scans as…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Risk factors for cardiotoxic events in patients treated with immune checkpoint inhibitors - 1 year(s) ago
Han Zhu, MD, Stanford University, Standford, CA, discusses risk factors for cardiotoxic events in patients treated with immune checkpoint inhibitors….
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Key updates in immunotherapies for melanoma - 1 year(s) ago
Diwakar Davar, MD, UPMC Hillman Cancer Center, Pittsburgh, PA, discusses recent advances in the field of immunotherapy for patients with…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1PDS0101 Plus Chemoradiation Elicits 100% ORR in High-Risk Locally Advanced Cervical Cancer - 1 year(s) ago
PDS0101 given in conjunction with chemoradiation elicited an 100% overall response rate, along with tumor shrinkage greater than 60%, in 9 patients with high-risk, locally advanced cervical cancer, according to results of the phase 2 IMMUNOCERV trial.
Source: OncLiveCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0The role of myeloid cells in TME - 1 year(s) ago
Judith Varner, PhD, University of California, San Diego, CA, discusses the role of myeloid cells in the tumor microenvironment (TME)…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Collagen fiber + immune architecture as novel biomarker for gynecological cancers treated with IO - 1 year(s) ago
Anant Madabhushi, PhD, Emory University School of Medicine, Atlanta, GA, discusses the association between the combination of novel biomarkers of…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 1
Han Zhu, MD, Stanford University, Standford, CA, discusses immune-mediated mechanisms in checkpoint inhibitor-induced myocarditis and investigating druggable targets as well…
Source: VJOncologyCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
🎥 @HanZhuMD of @Stanford discusses remaining challenges in reducing or preventing cardiotoxicity in patients receiving immunotherapy Watch: 👉https://t.co/fnDyhK5oG6👈 @sitcancer #SITC2022 #SITC22 #ImmunoOnc